Form 4: Capricor Therapeutics Director Awarded Stock Options for Board Service

A director at Capricor Therapeutics, Inc. has been granted stock options as part of their compensation for board and committee service.

Summary

• Capricor Therapeutics, Inc. director Mike Kelliher has been awarded stock options as part of his compensation.
• The options were granted on January 2, 2025, with an exercise price of $14.96.
• A total of 19,130 stock options were granted.
• 11,940 options are for annual board service and will vest monthly over one year, starting February 1, 2025.
• The remaining options, 1,440 for annual board committee service and 5,750 for annual board service, are fully vested and exercisable as of the grant date.
• All options expire on January 2, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive, as the option grants align the director's interests with shareholders, but the lack of information on the current stock price and the potential for dilution limit a more positive assessment.

Positives

• The grant of stock options aligns the director's interests with those of shareholders.
• The vesting schedule for a portion of the options encourages continued service on the board.
• Immediate vesting of some options recognizes the director's current contributions.

Negatives

• The document does not disclose the current market price of Capricor's stock, making it difficult to assess the immediate value of the options.
• Stock options can dilute existing shareholders' equity if exercised.

Risks

• The value of the options is dependent on the future performance of Capricor's stock price.
• If the stock price falls below the exercise price, the options may become worthless.
• Changes in market conditions or company performance could negatively impact the value of the options.

Future Outlook

The document does not contain any explicit forward-looking statements.

Industry Context

This announcement is typical for public companies, which often use stock options as a form of compensation for directors and executives. It reflects standard practices in corporate governance within the biotechnology and pharmaceutical industry.

Comparison to Industry Standards

• The use of stock options for director compensation is a common practice among biotechnology companies.
• For example, companies like Amgen (AMGN) and Gilead Sciences (GILD) also utilize stock options in their executive and director compensation packages.
• Compared to these industry giants, Capricor's option plan appears to be in line with standard practices, although the specific exercise price and vesting schedules may vary.
• The exercise price of $14.96 is not directly comparable to peers without knowing Capricor's stock price at the time of grant, but the structure of the awards is consistent with industry norms.

Stakeholder Impact

• Shareholders: Potential dilution of equity if options are exercised.
• Director: Incentive to contribute to the company's success, potentially increasing shareholder value.

Next Steps

• Mike Kelliher may choose to exercise the vested options at any time before their expiration.
• The 11,940 options will continue to vest monthly until fully vested on December 31, 2025.

Key Dates

Keywords

Capricor Therapeutics, CAPR, stock options, board of directors, compensation, vesting, SEC Form 4, insider transaction, equity securities, Mike Kelliher